SMARCA4 and non-small cell lung carcinoma: For instance, CDK4/6 inhibitors can sensitise BRG1-defective cancer cells, especially in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) and Non-small cell lung cancer (NSCLC) due to the downregulation of cyclin D1 (Xue et al., 2019a; Xue et al., 2019b).